68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Status:
Not yet recruiting
Trial end date:
2028-08-31
Target enrollment:
Participant gender:
Summary
Somatostatin receptor (SSR) imaging is a critical component of clinical care for many
patients being investigated for or with confirmed SSR positive tumors. In the past,
111In-octreotide imaging has been used for this purpose but it has been recently supplanted
globally by SSR positron emission tomography (PET) imaging due to better image quality and
higher diagnostic accuracy.
This study will assess the safety and diagnostic effectiveness of 68Ga-HA-DOTATATE produced a
the Edmonton Radiopharmaceutical Centre (ERC).